All News

Efforts to more precisely select appropriate therapy for individual patients with rheumatoid arthritis have not yet yielded a clear-cut strategy, a new review finds.

Raymond Osarogiagbon, MD, discusses the challenges of implementing lung cancer screening guidelines and the need for increased awareness and access.

Combining immunotherapy with chemotherapy shows promise in enhancing survival rates for extensive-stage small cell lung cancer (ES-SCLC).

With artificial intelligence (AI) capabilities freeing up workers and driving billions in gains, pharmacy may soon see a 75% workload drop.

Early actions by the new administration signal major changes in health policy, taxes, and pharmaceutical pricing.

Prior studies have shown that women may absorb cancer therapies differently than men, but this study focused on the fallout on patients' physical activity and quality of life.

From a meeting that celebrates basic research and being "first," a look at 3 data sets on therapies that would break new ground.

Medicaid beneficiaries face higher rates of pulmonary hypertension, with significant economic burdens and racial disparities in prevalence and costs.

Kimlin Tam Ashing, PhD, of City of Hope National Medical Center, emphasizes the vital role of community engagement in cancer research, enhancing trust and communication between scientists and communities.

Smoking prevalence is projected to decline by 2035, yet health consequences persist due to slower reductions among older adults.

Immediate local flap or skin graft following basal cell carcinoma (BCC) can be considered, a study found.

New research suggests classical biomarkers cannot discriminate between refractory and non-refractory rheumatoid arthritis.

Artificial intelligence (AI) has the potential to deliver personalized nutrition; however, there is a need for professional oversight, emphasized Julia Logan, BS.

Results could give patients with HER2-mutated non–small cell lung cancer (NSCLC) an oral therapy option.

John Heymach, MD, PhD, The University of Texas MD Anderson Cancer Center, discusses the promising results of zongertinib for HER2-mutated non–small cell lung cancer, showcasing high response rates and improved patient quality of life.

Minimal residual disease (MRD)-guided triple therapy showed promising results for relapsed chronic lymphocytic leukemia (CLL), achieving high rates of undetectable disease and prolonged survival.

Julia Logan, BS, discusses the vital role of nutrition in cancer care, highlighting how artificial intelligence can enhance dietary recommendations for patients.

Luis Carvajal-Carmona, PhD, stresses the importance of global collaboration in cancer research to enhance understanding and treatment across diverse populations.

Ravindra Uppaluri, MD, PhD, lead investigator of the phase 3 KEYNOTE-689 trial (NCT03765918), highlights the need for a multidisciplinary approach to translate the study's findings into real-world care for patients with resectable head and neck cancer.

Ravindra Uppaluri, MD, PhD, lead investigator of the phase 3 KEYNOTE-689 trial (NCT03765918), highlights the potential of pembrolizumab (Keytruda; Merck) to improve outcomes following head and neck cancer treatment.

Andrew Kuykendall, MD, is an investigator on the phase 3 VERIFY trial (NCT05210790), findings from which demonstrate the safety, reliability, and effectiveness of rusfertide to treat polycythemia vera.

New research explores the complex relationship between female infertility and gynecological cancers, revealing minimal links and emphasizing the need for further studies.

The findings highlight important differences between therapies in managing blood glucose, blood pressure, lipids, and adverse effects in this high-risk patient population.

Adding venetoclax to decitabine-cedazuridine significantly enhanced response rates in patients with higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia.

Tocilizumab has emerged as a key treatment for rheumatoid arthritis, showing efficacy, safety, and potential cardiovascular benefits in recent studies.

As the Affordable Care Act passed its 15th anniversary this year, Supreme Court Justices continue to deliberate the fate of its preventive services mandate in Kennedy v Braidwood.

Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related health issues, but it also risks adding tens of billions in new costs, highlighting the need for smart policy strategies to ensure access, affordability, and long-term sustainability.

When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.